Epiteloid anjiyomiyolipom (EAML), epiteloid PEComa olarak da adlandırılan, hücrelerinin en az %80’i epiteloid morfoloji gösteren, anjiyomiyolipomun nadir ve malign bir varyantıdır. Sporadik olarak gelişebileceği gibi tüberoskleroz kompleksi (TSK) ile ilişkili de olabilir. Patogenezde, 16p13 kromozomundaki TSC2 geninde biallelik inaktivasyon sonucu mTOR yolağının aktivasyonu meydana gelir ve bu durum kontrolsüz hücresel proliferasyona yol açar. Bazı olgularda TFE3 geninde yeniden düzenlenme veya amplifikasyon izlenir ve bu durum daha agresif klinik seyirle ilişkilidir. EAML genellikle yaşamın beşinci dekadında ortaya çıkar ve kadın-erkek oranı eşittir. Tümörler genellikle büyük, solid ve hemorajiktir, sıklıkla nekroz gösterir. Mikroskopik olarak iki büyüme paterni tanımlanır: Karsinom benzeri patern (Patern A) — pleomorfik epiteloid hücreler, belirgin nükleoller ve ganglion benzeri dev hücreler içerir — ve diffüz patern (Patern B) — uniform epiteloid veya dolgun iğsi hücrelerden oluşur. İmmünohistokimyasal olarak tümör hücreleri HMB45, Melan-A, MITF, Katepsin K ve SMA pozitiftir; keratin ve PAX8 ekspresyonu göstermez. EAML malignite potansiyeline sahiptir; olguların %23–35’inde lokal ileri hastalık ve yaklaşık %49’unda metastaz (en sık karaciğer, akciğer ve periton) bildirilmiştir. Tedavi, cerrahi rezeksiyon (parsiyel veya radikal nefrektomi) ve rezeksiyon yapılamayan olgularda mTOR inhibitörlerinin kullanımını içerir. Prognoz; nekroz varlığı, mitotik aktivite ve TFE3 değişiklikleriyle ilişkilidir.
Non-invasive papillary urothelial carcinoma (NIPUC) is currently classified in a two-tier system, and some cases exhibit mixed low- and high-grade morphology. We aimed to evaluate the detailed morphological features of mixed NIPUC and determine the impact of histopathologic features on grade and stage progression. A total of 106 primary and follow-up bladder specimens of 28 patients with a diagnosis of mixed NIPUC were retrieved. Pathological parameters were specified as the volume of biopsy, percentages of 2-tier (low-high) and 4-tier (Grade 1-4) grades, hot-spot mitotic count, and the location of mitosis, discohesion, and the presence of whirling. Outcome measures were the grade trend (decline or incline) and stage progression. The mean age was 65 (range, 35-81), and all but two were male. Ten patients had a previous biopsy showing pure low-grade NIPUC. Patients with more than 5% high-grade areas (n=14) were classified as high-grade according to the 2-tier grading system. The mean distributions of G1-G4 in mixed NIPUCs at the zero-point were 42%, 42%, 15%, and 1%, respectively. Tumors with more than 85% grade 1 histology did not exhibit an upward trend in grade. Stage progression was observed in tumors with a total percentage of grade 3 and grade 4 (high-grade) areas ≥5%(p=0.031). Grade trend was directly correlated with stage progression(p=0.012). Mixed NIPUC has variable clinical outcomes that depend on the proportion of grade 1 areas (>85%), suggesting a non-inclining grade trend in follow-up biopsies and the presence of ≥5% high-grade (grade 3 and 4) morphology, suggesting stage progression.
Klasik anjiyomiyolipom (AML), diğer adıyla perivasküler epiteloid hücreli tümör (PEComa), değişen oranlarda yağ dokusu, düz kas hücreleri ve kalın duvarlı damarlar içeren benign bir mezenkimal tümördür. Böbrek tümörlerinin yaklaşık %1’ini oluşturur. Sporadik olgular genellikle yaşlı kadınlarda tek taraflı ve soliterdir, tüberoskleroz zemininde gelişen olgular ise sıklıkla bilateral ve multifokaldir. Patogenezde, TSC1 veya TSC2 genlerinde biallelik inaktivasyon sonucu mTOR yolağının aşırı aktivasyonu gelişir ve bu da hücre proliferasyonunu artırır. Histolojik olarak AML, adipöz doku, iğsi veya epiteloid düz kas hücreleri ve displastik kalın duvarlı damarlar içerir. İmmünohistokimyasal olarak HMB45, Melan-A, Katepsin K, SMA ve Desmin pozitif, keratin negatiftir. Bu boyanma paterni myomelanositik farklılaşmayı doğrular. Klinik olarak çoğu olgu asemptomatiktir, ancak yan ağrısı, hematüri veya retroperitoneal hemoraji (Wunderlich sendromu) ile ortaya çıkabilir. Tedavide cerrahi eksizyon ve anjiyografik embolizasyon uygulanır; büyük veya çoklu lezyonlarda mTOR inhibitörleri etkili olabilir. AML genellikle benign seyirli olmasına rağmen, nadiren sarkomatöz transformasyon ve metastaz bildirilmiştir; bu nedenle uzun dönem takip önerilir.
Background: Breast cancer brain metastases (BCBMs) are clinically challenging, and treatment decisions are influenced by tumor biology. Because receptor profiles may differ between primary breast tumors and brain metastases and brain biopsy may be impractical, non-invasive imaging biomarkers may provide useful biologic correlates. We evaluated whether diffusion-weighted imaging (DWI)-derived apparent diffusion coefficient (ADC) histogram metrics from BCBM were associated with primary tumor estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status; the Ki-67 proliferation index; and luminal status. Methods: This retrospective exploratory single-center study included 72 adults with BCBM who underwent standardized 1.5T brain magnetic resonance imaging. The largest lesion in each patient was segmented on ADC maps in FireVoxel. ADC histogram features, including percentiles, were extracted. Using primary tumor biomarker status as the reference, candidate metrics were screened by univariable logistic regression. Parsimonious multivariable models included age, log-transformed lesion volume, and a single selected ADC percentile scaled by ×10. Discriminatory performance was assessed using area under the receiver operating characteristic curve (AUC); thresholds were derived with the Youden index. No external validation was performed. Results: Low-percentile ADC metrics were associated with ER positivity, PR positivity, and luminal disease, whereas no meaningful ADC histogram discrimination was observed for HER2. In multivariable models, ADC10×10 predicted ER positivity (odds ratio [OR] 0.441; AUC 0.847) and PR positivity (OR 0.478; AUC 0.819). Ki-67 positivity was best predicted by ADC75×10 (OR 3.095; AUC 0.905), although this finding should be interpreted cautiously. Luminal status (non-luminal vs. luminal) was predicted by ADC10×10 (OR 2.251; AUC 0.832). Conclusions: ADC histogram analysis from DWI in BCBM showed exploratory associations with primary tumor hormone receptor status and luminal subtype, but not HER2. These findings support ADC histogram features as candidate imaging biomarkers, but the Ki-67 result and all model performance estimates require cautious interpretation and independent external validation in multicenter cohorts.